S

SymBio Pharmaceuticals Ltd
TSE:4582

Watchlist Manager
SymBio Pharmaceuticals Ltd
TSE:4582
Watchlist
Price: 91 JPY 1.11% Market Closed
Market Cap: 5.1B JPY

Net Margin
SymBio Pharmaceuticals Ltd

-298.6%
Current
-92%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-298.6%
=
Net Income
-4.6B
/
Revenue
1.5B

Net Margin Across Competitors

No Stocks Found

SymBio Pharmaceuticals Ltd
Glance View

Market Cap
4.7B JPY
Industry
Pharmaceuticals

SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 141 full-time employees. The company went IPO on 2011-10-20. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The firm develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The firm manufactures and sells medicines through domestic and foreign pharmaceutical companies. The firm's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.

Intrinsic Value
69.41 JPY
Overvaluation 24%
Intrinsic Value
Price
S
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-298.6%
=
Net Income
-4.6B
/
Revenue
1.5B
What is the Net Margin of SymBio Pharmaceuticals Ltd?

Based on SymBio Pharmaceuticals Ltd's most recent financial statements, the company has Net Margin of -298.6%.

Back to Top